Torrent Pharma Fined ₹41 Crore Over Alleged Incorrect GST Refund Claims

Torrent Pharmaceuticals has been served a penalty of ₹41 crore (₹ 41,33,84,165) by the Central GST Ahmedabad South Commissionerate for alleged wrongful GST refund claims related to its goods exports. The company plans to appeal the order, maintaining that there will be no significant financial impact. 

₹41 Crore Penalty Over Alleged GST Refund Discrepancy 

On November 28, 2025, Torrent Pharmaceuticals informed the stock exchanges that it received a penalty order of ₹41 crore issued by a Joint Commissioner of the Central GST, Ahmedabad South Commissionerate.  

The penalty arises from allegations of claiming GST refunds wrongly on goods exported under Section 74 of the CGST Act, 2017. This section covers tax not paid, short-paid, or wrongly refunded due to suppression or misstatement of facts. 

Company’s Response and Appeal Plans 

The company has stated that it will appeal against the penalty order. Torrent Pharma expressed confidence in obtaining relief through the appellate process. In its regulatory filing, it reassured stakeholders that there would be no material financial impact and all operations would continue uninterrupted during the legal process. 

Read More: Glenmark Pharma Share Price Gains 2% After US FDA Issues Positive Inspection Report! 

Torrent Pharmaceuticals Share Price Performance  

As of November 28, 2025, at 3:00 PM, Torrent Pharmaceuticals share price on NSE was ₹3723.90 down by 0.17% from the previous closing price. 

Conclusion 

Torrent Pharmaceuticals has been fined ₹41 crore in relation to alleged erroneous GST refund claims. With the company preparing to appeal the decision, it has assured stakeholders of stable operations and limited financial repercussions from the issue. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.